Key result
Oral Lactobacillus paracasei GMNL-32 reduces cardiac apoptosis and fibrosis in lupus-prone mice.
Why the study?
Does oral administration of Lactobacillus paracasei GMNL-32 improve cardiac abnormalities in female NZB/W F1 lupus-prone mice?
Does oral administration of Lactobacillus paracasei GMNL-32 improve cardiac abnormalities in female NZB/W F1 lupus-prone mice?
Lactobacillus paracasei GMNL-32 demonstrates protective anti-fibrotic and anti-apoptotic effects on cardiac tissue in a lupus-prone mouse model, suggesting potential therapeutic value for SLE-associated cardiovascular disease.
No immediate clinical implications in SLE; leaves open whether probiotic cardiac effects translate beyond lupus mouse models.
Systemic lupus erythematosus (SLE) is a disease that mostly affects women. Accelerated atherosclerosis is a high-risk factor associated with SLE patients. SLE associated with cardiovascular disease is one of the most important causes of death. In this study, we demonstrated that Lactobacillus paracasei GMNL-32 (GMNL-32), a probiotic species, exhibits anti-fibrosis and anti-apoptotic effects on the cardiac tissue of NZB/WF1 mice. Female NZB/W F1 mice, a well-known and commonly used lupus-prone mouse strain, were treated with or without GMNL-32 administration for 12 weeks. Oral administration of GMNL-32 to NZB/WF1 mice significantly increased the ventricular thickness when compared to that of NZB/WF1 mice. Administration of GMNL-32 significantly attenuated the cardiac cell apoptosis that was observed in exacerbate levels in the control NZB/WF1 mice. Further, the cellular morphology that was slightly distorted in the NZB/WF1 was effectively alleviated in the treatment group mice. In addition, GMNL-32 reduced the level of Fas death receptor-related pathway of apoptosis signaling and enhanced anti-apoptotic proteins. These results indicate that GMNL-32 exhibit an effective protective effect on cardiac cells of SLE mice. Thus, GMNL-32 may be a potential therapeutic strategy against SLE associated arthrosclerosis.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2017) studied Systemic lupus erythematosus (SLE) (n=20). Lactobacillus paracasei GMNL-32 vs. Oral saline solution was evaluated on Cardiac abnormalities (apoptosis, fibrosis, and ventricular thickness). Oral administration of Lactobacillus paracasei GMNL-32 significantly attenuated cardiac cell apoptosis, reduced fibrosis, and increased ventricular thickness in lupus-prone NZB/W F1 mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: